Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life
Market Cap
$1.06 Billion
CN¥7.75 Billion CNY
Market Cap Rank
#12282 Global
#3017 in China
Share Price
CN¥1.58
Change (1 day)
+0.00%
52-Week Range
CN¥1.39 - CN¥4.03
All Time High
CN¥10.45
Categories
Companies in China Insurance - Life
About

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more

Hubei Biocause Pharmaceutical (000627) - Net Assets

Latest net assets as of September 2024: CN¥36.00 Billion CNY

Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has net assets worth CN¥36.00 Billion CNY as of September 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥285.15 Billion) and total liabilities (CN¥249.15 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥36.00 Billion
% of Total Assets 12.63%
Annual Growth Rate 19.18%
5-Year Change -2.1%
10-Year Change 2157.69%
Growth Volatility 211.8

Hubei Biocause Pharmaceutical - Net Assets Trend (2000–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Hubei Biocause Pharmaceutical (2000–2023)

The table below shows the annual net assets of Hubei Biocause Pharmaceutical from 2000 to 2023.

Year Net Assets Change
2023-12-31 CN¥33.63 Billion -2.80%
2022-12-31 CN¥34.60 Billion -7.66%
2021-12-31 CN¥37.47 Billion +8.35%
2020-12-31 CN¥34.59 Billion +0.68%
2019-12-31 CN¥34.35 Billion +32.05%
2018-12-31 CN¥26.01 Billion -2.58%
2017-12-31 CN¥26.70 Billion +30.92%
2016-12-31 CN¥20.40 Billion +1043.54%
2015-12-31 CN¥1.78 Billion +19.73%
2014-12-31 CN¥1.49 Billion +3.72%
2013-12-31 CN¥1.44 Billion -6.58%
2012-12-31 CN¥1.54 Billion +8.71%
2011-12-31 CN¥1.41 Billion -11.73%
2010-12-31 CN¥1.60 Billion +1.75%
2009-12-31 CN¥1.57 Billion +4.08%
2008-12-31 CN¥1.51 Billion +74.68%
2007-12-31 CN¥866.03 Million +19.67%
2006-12-31 CN¥723.71 Million -1.03%
2005-12-31 CN¥731.23 Million +1.01%
2004-12-31 CN¥723.91 Million +0.72%
2003-12-31 CN¥718.75 Million -6.41%
2002-12-31 CN¥768.02 Million +0.66%
2001-12-31 CN¥762.99 Million +28.34%
2000-12-31 CN¥594.52 Million --

Equity Component Analysis

This analysis shows how different components contribute to Hubei Biocause Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 7134.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2023)

Component Amount Percentage
Retained Earnings CN¥5.31 Billion 25.79%
Other Components CN¥15.28 Billion 74.21%
Total Equity CN¥20.59 Billion 100.00%

Hubei Biocause Pharmaceutical Competitors by Market Cap

The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their market capitalization.

Company Market Cap
Palm Landscape Architecture Co Ltd
SHE:002431
 		$336.33 Million
Jahwa Electron
KO:033240
 		$336.42 Million
Nexus Real Estate Investment Trust
PINK:EFRTF
 		$336.47 Million
Nanjing Doron Technology Corp
SHG:603528
 		$336.50 Million
Jiangxi Salt Industry Group Co. Ltd. A
SHG:601065
 		$335.96 Million
Samkang M&T Co.Ltd
KQ:100090
 		$335.94 Million
Hirose Electric Co.Ltd
PINK:HROEY
 		$335.82 Million
Creades AB
ST:CRED-A
 		$335.82 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hubei Biocause Pharmaceutical's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2022 to 2023, total equity changed from 21,411,955,514 to 20,590,055,885, a change of -821,899,628 (-3.8%).
  • Net loss of 651,758,543 reduced equity.
  • Dividend payments of 1,413,018,160 reduced retained earnings.
  • Other factors increased equity by 1,242,877,074.

Equity Change Factors (2022 to 2023)

Factor Impact Contribution
Net Income CN¥-651.76 Million -3.17%
Dividends Paid CN¥1.41 Billion -6.86%
Other Changes CN¥1.24 Billion +6.04%
Total Change CN¥- -3.84%

Book Value vs Market Value Analysis

This analysis compares Hubei Biocause Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.38x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 CN¥3.91 CN¥1.58 x
2018-12-31 CN¥3.84 CN¥1.58 x
2019-12-31 CN¥4.30 CN¥1.58 x
2020-12-31 CN¥4.28 CN¥1.58 x
2021-12-31 CN¥4.56 CN¥1.58 x
2022-12-31 CN¥4.33 CN¥1.58 x
2023-12-31 CN¥4.17 CN¥1.58 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hubei Biocause Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -3.17%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1.31%
  • • Asset Turnover: 0.16x
  • • Equity Multiplier: 14.66x
  • Recent ROE (-3.17%) is below the historical average (4.71%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 6.49% 10.64% 0.36x 1.68x CN¥-18.53 Million
2001 5.41% 10.46% 0.36x 1.44x CN¥-31.64 Million
2002 0.76% 1.51% 0.32x 1.57x CN¥-64.13 Million
2004 0.78% 1.10% 0.43x 1.66x CN¥-60.00 Million
2005 1.08% 1.37% 0.48x 1.65x CN¥-58.71 Million
2006 6.84% 8.63% 0.48x 1.65x CN¥-22.34 Million
2007 12.28% 11.97% 0.63x 1.63x CN¥18.60 Million
2008 1.20% 1.93% 0.46x 1.35x CN¥-128.65 Million
2009 3.31% 5.21% 0.45x 1.42x CN¥-101.55 Million
2010 1.83% 2.25% 0.64x 1.28x CN¥-126.18 Million
2012 0.79% 1.52% 0.38x 1.38x CN¥-137.92 Million
2014 5.78% 7.40% 0.54x 1.46x CN¥-61.08 Million
2015 14.21% 22.89% 0.45x 1.38x CN¥73.30 Million
2016 12.89% 21.74% 0.07x 8.54x CN¥398.54 Million
2017 6.86% 14.76% 0.06x 7.26x CN¥-607.54 Million
2018 6.98% 12.01% 0.06x 9.39x CN¥-572.69 Million
2019 8.37% 14.08% 0.06x 9.67x CN¥-346.37 Million
2020 2.75% 4.72% 0.05x 11.33x CN¥-1.53 Billion
2021 2.09% 3.86% 0.05x 11.70x CN¥-1.78 Billion
2022 1.28% 0.55% 0.17x 13.48x CN¥-1.87 Billion
2023 -3.17% -1.31% 0.16x 14.66x CN¥-2.71 Billion

Industry Comparison

This section compares Hubei Biocause Pharmaceutical's net assets metrics with peer companies in the Insurance - Life industry.

Industry Context

  • Industry: Insurance - Life
  • Average net assets among peers: $26,486,814,697
  • Average return on equity (ROE) among peers: 3.85%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Hubei Biocause Pharmaceutical (000627) CN¥36.00 Billion 6.49% 6.92x $336.31 Million
COFCO Capital Holdings Co Ltd (002423) $26.49 Billion 3.85% 3.71x $985.29 Million